Doreen Brettler to Recombinant Proteins
This is a "connection" page, showing publications Doreen Brettler has written about Recombinant Proteins.
Connection Strength
0.055
-
Brettler D. A 3.5-year study of immune function in persons with hemophilia infusing recombinant factor VIII. Ann Hematol. 1994; 68 Suppl 3:S49-50.
Score: 0.023
-
Engelfriet CP, Reesink HW, Mannucci PM, Gringeri A, Ingerslev J, Brettler DB, Mauser-Bunschoten EP, Negrier C, Berntorp E, Smith OP, Shapiro AD. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies. Vox Sang. 2000; 78(4):256-61.
Score: 0.009
-
Shopnick RI, Kazemi M, Brettler DB, Buckwalter C, Yang L, Bray G, Gomperts ED. Anaphylaxis after treatment with recombinant factor VIII. Transfusion. 1996 Apr; 36(4):358-61.
Score: 0.007
-
Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group. Blood. 1994 Apr 01; 83(7):1958-62.
Score: 0.006
-
Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettler DB, Rosenberg RD. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood. 1992 Apr 15; 79(8):2039-47.
Score: 0.005
-
Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med. 1990 Dec 27; 323(26):1800-5.
Score: 0.005